The Need for Balance in Evaluating the Evidence on Na and CVD

Similar documents
Salt reduction - benefits beyond blood pressure

Health Benefits of Lowering Sodium Intake in the US

The Evidence for Populationwide Reduction in Sodium Intake: Why All the Fuss?

Diabetes Mellitus: A Cardiovascular Disease

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

IS IT TIME TO REDUCE SALT IN SOUTH AFRICAN FOOD? KRISELA STEYN DEPT OF MEDICINE, UCT CHRONIC DISEASES INITIATIVE IN AFRICA

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

Sodium and Health: Evidence, Policy, Reality

Sodium and Potassium Intake and Cardiovascular and Bone Health:

Mesures non médicamenteuses pour prévenir et traiter une hypertension artérielle. JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Why you should take the latest sodium study with a huge grain of salt

Cardiovascular Outcome

What s In the New Hypertension Guidelines?

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Hypertension Management Controversies in the Elderly Patient

Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)

Using the New Hypertension Guidelines

NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N

The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)

Primary Physiological

Diet-Related Factors, Educational Levels and Blood Pressure in a Chinese Population Sample: Findings from the Japan-China Cooperative Research Project

Blood Pressure LIMBO How Low To Go?

Results/ conclusion. Reference Duration Number subjects. Study description. Limitations of the data. Randomized controlled trial (RCT)

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Heart Disease Genesis

Professor Clare Collins

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

Blood Pressure Acre Surgery Diviash Thakrar

How Low Do We Go? Update on Hypertension

Risk Factors for Heart Disease

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Fasting or non fasting?

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

T. Suithichaiyakul Cardiomed Chula

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Analyzing diastolic and systolic blood pressure individually or jointly?

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Value of cardiac rehabilitation Prof. Dr. L Vanhees

Examining the relationship between beverage intake and cardiovascular health. Ian Macdonald University of Nottingham UK

Hypertension JNC 8 (2014)

L III: DIETARY APPROACH

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Diabetes, Diet and SMI: How can we make a difference?

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Antihypertensive Trial Design ALLHAT

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Report Operation Heart to Heart

Sugar-Loaded Beverages and the Impact on Cardiovascular Health. Christina M. Shay, PhD, MA

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

Objectives. Heart failure and Hypertension. Definition & epidemiology of heart failure HEART FAILURE 3/12/2016. Kirsten Bibbins-Domingo, PhD, MD, MAS

Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease

CVD Prevention, Who to Consider

Treating Hypertension in 2018: What Makes the Most Sense Today?

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Adolescent Hypertension Roles of obesity and hyperuricemia. Daniel Landau, MD Pediatrics, Soroka University Medical Center

Since 1980, obesity has more than doubled worldwide, and in 2008 over 1.5 billion adults aged 20 years were overweight.

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

A cross-sectional study on association of calcium intake with blood pressure in Japanese population

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Of Cows and Men: Reviewing the Link Between Dairy Fat and Human Health

CVD Prevention at work place settings

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Guidelines on cardiovascular risk assessment and management

Adherence to a healthy diet in relation to cardiovascular incidence and risk markers: evidence from the Caerphilly Prospective Study

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Salt: How much less should we eat for health? Understanding the recent IOM report

Role of Minerals in Hypertension

International model for prevention of chronic disease: Finland experience

1. Which one of the following patients does not need to be screened for hyperlipidemia:

The Clinical Unmet need in the patient with Diabetes and ACS

Systolic Blood Pressure Intervention Trial (SPRINT)

For instance, it can harden the arteries, decreasing the flow of blood and oxygen to the heart. This reduced flow can cause

Molly Miller, M.S., R.D., Thomas Boileau, Ph.D.,

American Academy of Insurance Medicine

ASSeSSing the risk of fatal cardiovascular disease

Blood Pressure Measurement in SPRINT

Management of Hypertension in Women

Disclaimer for sharing or use of any of this presentation

The New Hypertension Guidelines

Mean INTERHEART Risk Score (IHRS) Yusuf et al NEJM 2014

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Prevention of MACROvascular Complications of Diabetes

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Evidence-based priority setting for dietary policies. Ashkan Afshin, MD MPH MSc ScD November 17, 2016 Acting Assistant Professor of Global Health

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

American Diabetes Association: Standards of Medical Care in Diabetes 2015

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Methods. OR and PAR both presented with 99% confidence intervals. All analyses adjusted for age, sex and region.

Overall Assessment: Good level of support for target although there were some concerns on achievability.

Dietary intake in male and female smokers, ex-smokers, and never smokers: The INTERMAP Study

10/21/2014. Disclosures. Introduction. Reasons for the Decline in Stroke Mortality: Implications for Hypertension and Risk Factor Management

Achieving a Culture of Employee Health and Wellness

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Not For Distribution

Transcription:

The Need for Balance in Evaluating the Evidence on Na and CVD Salim Yusuf Professor of Medicine, McMaster University Executive Director, Population Health Research Institute Vice-President Research, Hamilton Health Sciences President-Elect ( 2013 onwards) World Heart Federation I have no relationships that will influence my judgments or the conclusions of my work, no association with any food manufacturer or those committed to salt polices.

BMJ July 30, 1988: A tale of two study reports Urinary electrolyte excretion, alcohol consumption, and BP on the Scottish Heart Health Study Smith WC, Crombie IK, Tavendale RT, Gulland SK and Turnstall-Pedoe HD. Number of citations = 83 Intersalt: an international study of electrolyte excretion and BP: results for 24 hour urinary Na and K excretion. Number of citations = 622

Scottish Heart Study 24 hour urine in 7354 random individuals (40-59 yrs) from 22 districts in Scotland. Several significant correlations with both SBP and DBP but only the co-efficients for age, BMI and pulse rate were >0.1 -alcohol and sodium excretion showed a weak positive correlation with BP; and K+ excretion a weak inverse correlation with BP In multiple regression, age, pulse rate, BMI, alcohol and K+ excretion (but not sodium excretion) correlated with BP. The most likely explanation is that the relation between Na and BP in the population is weak, and that K+, alcohol (and weight) are of greater importance.

INTERSALT: BMJ 1988 10,079 individuals 20 to 59 from 52 centers and many countries -4 centres (e.g. Yanomamo Indians*) with very low Na showed low BP and no upward slope of BP with age. Across the remaining 48 centers : -Na was NOT significantly related to BP (prespecified analysis), but to an increase in BP (slope) with age (data-derived emphasis) BMI, alcohol intake and K+ excretion were correlated with BP

INTERSALT(BMJ 1988): Median Na vs BP

INTERSALT(BMJ 1988): Slope of age related BP change vs Na

INTERSALT Revisited: BMJ 1996 Estimated diff in BP (mmhg) for 100 mmol higher 24 hr urinary sodium SBP DBP With BMI Without BMI With BMI Without BMI Not corrected 1.0 (0.3) 2.1 (0.3) 0.04 (0.19) 0.9 (0.2) Corrected for RDB 3.1 (0.9) 6.0 (1.1) 0.1 (0.6) 2.5 (0.7 Elliott BMJ 1996

Impact of different assumptions in modelling of 100 mmols/day % reduction in mortality Diff in SBP Stroke CHD Total 1 mmhg (1) -3-2 -1.5 2 mmhg (2) -6-4 -3.0 3 mmhg (3) -8-5 -4.0 6 mmhg (4) -18-12 -9.0 Diff in DBP.04 mmhg (1) None.09 mmhg (2) Negligible Negligible.10 mmhg (3) 2.5 mmhg (4) -12-7 -6.0 (1) Not corrected + BMI adjusted (2) Not corrected + BMI not adjusted (3) Corrected + BMI adjusted (4) Corrected + BMI not adjusted

Characteristics of the Yanomamo Indians vs US participants Yanomamo Indians# US (Chicago) SBP 95.4 115.1 DBP 61.4 70.0 U. Na (mmol/24 hrs) 0.2 133.8 U. K (mmol/24 hrs) 57.9 52.4 BMI 21.3 25.3 % Drinkers 0.0 70.0 U. Cr (mmol/24 hrs) 4.0* 12.1 *Indicates substantial under-collection of urine # Life expectancy <40 yrs.

Summary re: Sodium and BP There is a modest association between Na intake and BP, which is weaker (BMI) than or similar to other lifestyle factors (Potassium consumption or alcohol) The estimates of differences in BP have a 5 fold uncertainity( but most likely that 100 mmol=2.5 mmhg). A balanced approach to moderate changes in weight (e.g. 2.0 kg), alcohol consumption, activity and increase in fruits and vegetables, and animal products and Na consumption will lead to a larger BP & CVD reductions vs focussing on large reductions in Na. Such an approach is likely more feasible.

Meta-analysis of salt reduction on BP (He and McGregor) 31 trials on 3022 subjects included. 112 trials excluded (<4 wks, concomitant intervention, children/preg women, U Na not measured, reduction in U Na of <40 mmol/24 hrs) Not clear about losses to follow-up Some suggestion of publication bias (asymmetry in funnel plots ).

Meta-analysis of salt reduction on BP (He & McGregor) Hypertensives: Duration of 5 weeks, Median BP 149/94 mmhg 24 hr U Na : 165 mmol (9.5 g/day of salt), Reduced to 87 mmol (5.1 g/day of salt) SBP 5.06 mmhg (CI: -5.81 to -4.31) DBP -2.70 mmhg (CI: -3.16 to -2.24) Non-hypertensives: Duration of 4 weeks, Median BP 127/78 mmhg 24 hr U Na : 154 mmol (9.1g/day of salt), Reduced to 82 mmol (4.8 g/day) SBP -2.03 mmhg (-2.56 to -1.50) DBP -0.99 mmhg (-1.40 to - 0.57) N.B. In the long-term TOHP, Na (-44,33 mmols)& BP reductions (-1.7,1.2/.8,.7) were much smaller( Cook et al,bmj 2007) NOTE MANY STUDIES WITH LARGE EFECTS ARE FEEDING STUDIES OF VERY SHORT DURATION.

Variable validity of surrogate (physiologic) outcomes in CVD Reliable surrogates: Smoking, LDL-cholesterol Variable reliability: BP (NB several recent trials show little or no benefit from lowering BP (-140 mmhg) Consistently disappointing: HDL raising, suppression of ventricular arrhythmias, vascular reactivity, glucose lowering,??wt loss NET CLINICAL BENEFIT OF AN INTERVENTION IS A BALANCE OF MANY EFFECTS, AND CAN NOT BE PREDICTED FROM SURROGATE OUTCOMES.

Observational data related Na Intake to CVD Few large studies with >1000 events. Multiple 24 hr urines not practical; so spot (single/multiple) collections can estimate group means of Na intake. Dietary methods have greater variability, difficult to use in multiethnic populations due to variable sources of Na and differing patterns of diet. Measures of Na intake needs to positively associated with BP (not observed in several studies using diet). Confounding (need to adjust for BMI, alcohol, phys activity and other dietary components that affect BP or risk not collected in most studies) Reverse causality (can test/adjust for this, but impossible to completely exclude)

Value of Observational Studies Large prospective studies with careful assessment of exposures/confounders and a large number of outcomes (minimum 1000, ideally 5000 to 10,000+) can provide useful insights that can inform design of trials and policy. -if several studies show a similar pattern of information then the inference is more robust.

Estimated 24-Hour Urinary Excretion of Sodium and Composite of Cardiovascular Death, Stroke, Myocardial Infarction, and Hospitalization for Congestive Heart Failure :O Donnell et al JAMA 2011

PHRI s ongoing programme into Na (& other lifestyle factors) and BP PURE-Sodium: 1600 healthy Canadians from 4 sites with multiple 24 hr & spot urine + BP + Diet ( 2014) INTERSTROKE: 12,500 people with stroke & 12,500 controls ( 2013) Main PURE study: >135,000 people (out of 154,000 people) with second AM urine (+ regional comparisons to 24 hr urine) and CVD (3 yrs 10 yrs)( 2013 to 2020).

Very little reliable data from RCTs that Na reduction will reduce CVD.

TOHP Long Term Follow-up (5 to 10 years post trial) for CVD events Na reduction (n=327) TOHP I (n=744) Died 6 (2%) 12 (3%) Usual care (n=417) Responded 225 (69%) 299 (72%) No address, unwilling, no response 96 (30%) 106 (25%) Na reduction (n=1191) TOHP II (n=2382) Died 16 (1.5%) 24 (2%) Usual care (n=1191) Responded 922 (77%) 911 (77%) No address, unwilling, no response 124 (22%) 129 (21%) About 25% of randomized participants not followed Of 297 events, records only obtained in 196( ie 66%) Cook et al BMJ 2007

TOHP FU: Results on CVD & Total Mortality CVD (among responders i.e. in <75% of randomized) Overall 88/1169 (7.5%) Total mortality (in nearly all) Overall 35/1518 (2.3%) 112/1246 (9.0%) 42/1608 (2.6%) P (CMH) Adjusted HR and (p) 0.21 0.75 (p=0.044) 0.64 0.81 (p=0.35)

Projections of events prevented based on high estimates of BP decrease may be substantially inflated if the underlying assumptions are exaggerated. Moreover,these projections do not take into consideration the inconsistent or J shaped association of Na intake vs CVD events

Comparisons for SBP reductions used by Bibbins- Domingo compared to INTERSALT SBP reduction (mmhg) Salt reduction of 1 gm/day Salt reduction of 3 gm/day Low estimate High estimate Low estimate High estimate B-Domingo 0.60 1.17 1.80 3.51 INTERSALT Uncorr + adj 0.18 0.5 Corr+ adj 0.50 1.5 1 gm salt = 400 mg Na = 16 mmol Na (i.e. 1/3 SD change in Na) 3 gm salt = 1200 mg Na = 50 mmol Na (i.e. 1 SD change in Na)

Estimated annual number of heart attacks (in 1000 s) prevented from population wide Na reduction (based entirely on SBP reduction & assuming linear relationship) Hi estimate* Lo estimate* Intersalt Sodium reduction (a) by 400 mg/day Sodium reduction by (a) 1200 mg/day -32000-20000 -7000-92000 -58000-21000 Smoking cessation (b) -92000 Statin(1o Prev) (c) -17000 Drugs for HTN (c) -100000 (a) Observational data not robust; RCTs unreliable (b) Robust epidemiologic data (c) Robust RCT data *Estimates from Bibbins-Domingo; NEJM 2010 From Elliott, BMJ Intersalt, 1996: using SBP and NOT DBP.

Conclusions 1. There is a moderate association between Na intake and BP. A large difference in Na intake of 100 mmol difference (or 2300 mg) equates a 2 to 3 mmhg difference in SBP( projects to a 4% to 6% reduction in CVD (assuming no non-bp related adverse effects).a more feasible target is modest Na reduction ( eg 35-40 mmol ) which will translate into a 1.5 to 2% RR in CVD. 2. The totality of the observational data do not suggest a lower rate of CVD with Na consumption below 3.5 or 4 gms/day 3. Current RCT data are inconclusive as to whether lowering Na reduces CVD because they were not designed for this purpose. 4. Public health policy should be evidence based and would suggest that the degree of Na reduction that is feasible( 35-40 mmol/d) will lead to at best a small reduction in CVD in N America.

Implications 1. Need much better data on Na and CVD: - observational epidemiology with studies of >100,000 people with reliable measures of Na intake and >1000 to 10,000 events -RCTs to demonstrate unbiasedly and reliably that lowering Na is safe and effective in reducing CVD. 2. In the meantime, public health policy should be cautious and balanced: -encourage moderate reductions in Na ( to 3.5 or 4.0 gms/day), physical activity, wt loss, alcohol, fruits & veg, animal fats -encourage other lifestyle changes : smoking cessation -targetted use of low cost drugs in combination to reduce BP and lipids Such measures will reduce CVD by >2/3 to 3/4 in the next two decades, and will be far more effective, efficient and feasible than a policy of extreme Na reduction.

Sit down before fact as a little child, be prepared to give up every preconceived notion, follow humbly wherever and to whatever abyss nature leads, or you shall learn nothing Thomas Huxley